Japan Plans For iPS Industry Face Patent Blocks In U.S., Europe
This article was originally published in PharmAsia News
Executive Summary
Japan's plan to build a regenerative-medicine industry may already have run into a large obstacle in the form of patent practices in Europe and the U.S. that could limit vital sales of technologies and treatments.